Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8281 to 8295 of 8897 results

  1. The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)

    This appraisal has been updated and replaced by NICE guideline CG79. 

    Withdrawn guidance

  2. Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1110.

    Withdrawn guidance

  3. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1043.

    Withdrawn guidance

  4. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1040.

    Withdrawn guidance

  5. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA711)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA815.

    Withdrawn guidance

  6. Dapagliflozin for treating chronic kidney disease (TA775)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1075.

    Withdrawn guidance

  7. The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy (TA41)

    This guidance has been updated and replaced by NICE technology appraisal guidance 156. 

    Withdrawn guidance

  8. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

    This guidance has been updated and replaced by NICE technology appraisal guidance 653.

    Withdrawn guidance

  9. Human growth hormone for the treatment growth failure in children (TA42)

    This guidance has been updated and replaced by NICE technology appraisal guidance 188. 

    Withdrawn guidance

  10. Fremanezumab for preventing migraine (TA631)

    This guidance has been updated and replaced by NICE technology appraisal guidance 764.

    Withdrawn guidance

  11. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    This guidance has been updated and replaced by NICE technology appraisal guidance 836.

    Withdrawn guidance

  12. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  13. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  14. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654 

    Withdrawn guidance

  15. Sotagliflozin with insulin for treating type 1 diabetes (TA622)

    NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.  

    Withdrawn guidance